doi:10.1038/nature20580

Supplementary Methods

Data Acquisition and Preparation

Drug dose response data were downloaded from the CCLE (February 20, 2012; *CCLE_NP24.2009_Drug_data_2012.02.20.csv*) and CGP (Release 5, June 2014; *gdsc_drug_sensitivity_raw_data_w5.csv*) repositories and parsed to find matching cell line names. Original data files available upon request. As some cell lines have multiple names, several of the cell lines were matched manually to ensure maximal correspondence between the two databases. This identified 285 shared cell lines between CCLE and CGP (`CreateIntDataSheets.m`). The data were also parsed according to shared drugs (15). Viability values from CCLE were converted to percent viability by simply adding 100 to each value. In CGP, viability values possessed corresponding drug-free control wells (cells only) as well as drug- and cell-free wells. Viability values from CGP were converted to percent viability by subtracting the mean value from drug- and cell-free wells, dividing by the mean value from drug-free wells (which also has the mean value from drug- and cell-free wells subtracted), and then multiplying by 100.

Defining the Shared Dose Range

CCLE and CGP use different drug dose ranges. All drugs in CCLE have eight doses between 8 μM to 2.5 nM. Drugs in CGP each have different drug dose ranges for a total of nine doses, prepared by two-fold serial dilution. Because we wanted to compare the two databases within a similar drug dose range, the shared dose range boundary data points from each database were defined such that (*i*) the maximum number of data points from each database were used and (*ii*) the boundary data points from each database were as close to each other as possible (`FindSharedDoseRange.m`).

Calculation of Slope (*m*) and Area Under the Curve (*AUC*) Values

We calculated slope using the `polyfit` function and AUC using the `trapz` function in MATLAB. The x-values corresponded to $\log_{10}$ dose values. Because different drugs possess different drug dose ranges, we normalized slope and area under the curve to facilitate their comparison (`Calculatems.m` and `CalculateAUCs.m`, respectively). To normalize slope, we multiplied by the difference between the $\log_{10}$ of the maximum and minimum drug dose within the shared dose range, and divided by 100. To normalize AUC we divided by the difference between the $\log_{10}$ of the maximum and minimum drug dose within the shared dose range, and divided by 100.

SVM Machine Learning

The SVM classifer was trained with the MATLAB function `fitcsvm` (The Mathworks, Natick, MA) using a linear kernel. Predictors were the m_s and AUC_s measurements and the class labels were the average of the eight manual curator ratings of sensitivity or insensitivity rounded to the nearest integer (majority rules model).

Re-Calulating IC_{50} Values

IC_{50} values were re-calculated for every dose response curve in CCLE and CGP that was classified as sensitive in either database for the shared dose range only. A hill function was fit to the data using the MATLAB function `lsqcurvefit` and an IC_{50} was calculated

only if the hill function crossed the 50% viability line within the shared dose range, and otherwise omitted (`CalculateIC50SharedRange.m`).

Randomizing Dose Responses for Manual Curation

All of the dose response curves from the shared cell lines and drugs in CCLE and CGP (2520 curves from each study = 5040 total curves) were randomized such that each curator rated them in a unique order, using the MATLAB function `randperm`. Each curve was given a unique sequence of numbers that identified which database it was from and which cell line and drug was used. The manual curators were not given the key. The curators were only shown data that fell within the shared dose range (see Extended Data Figure 2 for an example page).

Producing Figures

All data analysis and figure preparation was done using MATLAB. The main figures can be reproduced using `FiguresMain.m` and the extended data figures using `FiguresExtendedData.m` which make use of custom made functions as well as a few downloaded from others[1,2,3]. All scripts and data needed to reproduce the figures are supplied as Supplementary Data File 2.

References

1. Cardillo G. (2007) Cohen's kappa: compute the Cohen's kappa ratio on a 2x2 matrix. *http://www.mathworks.com/matlabcentral/fileexchange/15365*
2. Charles (2011) cbrewer : colorbrewer schemes for Matlab. *http://www.mathworks.com/matlabcentral/fileexchange/34087*
3. Sanchez A. (2005) scatplot. *http://www.mathworks.com/matlabcentral/fileexchange/8577*


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


SHP-77
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

22RV1


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.9
AZD6244 (nM)
1.9 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.8
PLX4720 (nM)
2 2


CCLE
CGP
% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.9 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.1
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.4 2

786-0


CCLE
CGP
% Viability
17-AAG (nM)
1.6 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.8


CCLE
CGP
% Viability
17-AAG (nM)
1.6 1.6
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.3 2
PLX4720 (nM)
1.4 1.6
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2

8505C


CCLE
CGP
% Viability
100
50
0
1.3 1.4
17-AAG (nM)
1.5 2
AZD6244 (nM)
2 1.9
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.8 1.6
PD-0325901 (nM)
2 2
PD-0332991 (nM)
1.9 2
PLX4720 (nM)

A172


CCLE
CGP
% Viability
100
50
0
1.3
1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


CCLE
CGP
% Viability
100
50
0
1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
200
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
1.5 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


A253
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

A375


CCLE
CGP
% Viability
100
50
0
1.3 1.1
17-AAG (nM)
2 1.1
Nutlin-3 (nM)
2 1.1
PD-0332991 (nM)
1 1
PLX4720 (nM)
1.1 2
AZD6244 (nM)
2 2
Nilotinib (nM)
1 1.1
PD-0325901 (nM)
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}

A549


CCLE
CGP
% Viability
100
50
0
1.3 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
150
100
50
0
1.6 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

A673


CCLE
CGP
% Viability
100
50
0
1.3 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.8
PD-0332991 (nM)
2 2
PLX4720 (nM)

A2058


CCLE
CGP
% Viability
100
50
0
1.1 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.1 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

A2780


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
1.8 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.4 2
PD-0325901 (nM)
1.1 2
PD-0332991 (nM)
1.9 1.9
PLX4720 (nM)
2 2

ACHN


CCLE
CGP
% Viability
150
100
50
0
1.6 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

AN3-CA


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 1.9

AsPC-1


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.1
AZD6244 (nM)
1.6 1.3
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.4 1.8
PD-0332991 (nM)
2 1.5
PLX4720 (nM)
2 2

AU565


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.8
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 1.9

BCPAP


CCLE
CGP
% Viability
100
50
0
1.4 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 1.5
AZD6244 (nM)
150
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.6 1.9
PD-0325901 (nM)
2 1.9
PD-0332991 (nM)
1.3 1.8
PLX4720 (nM)

BFTC-909


CCLE
CGP
% Viability
100
50
0
1.1 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.8
PD-0332991 (nM)
2 2
PLX4720 (nM)

BL-41


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

BL-70


CCLE
CGP
% Viability
AZD0530 (nM)
Erlotinib (nM)
Lapatinib (nM)
Paclitaxel (nM)
PF2341066 (nM)
PHA-665752 (nM)
Sorafenib (nM)
TAE684 (nM)

BT-20


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

BT-474


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

BT-549


CCLE
CGP
% Viability
17-AAG (nM)
1 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.6 2

BxPC-3


CCLE
CGP
% Viability
100
50
0
1.4 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.9 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.4 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.5 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


C2BBe1
CCLE
CGP
% Viability
17-AAG (nM)
2 1.4
AZD0530 (nM)
1.3 1.3
AZD6244 (nM)
1.9 1.5
Erlotinib (nM)
1.9 2
Lapatinib (nM)
1.8 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.3
Paclitaxel (nM)
1.9 2
PD-0325901 (nM)
2 1.3
PD-0332991 (nM)
2 1.9
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 2
TAE684 (nM)
1.6 1.5

C3A


CCLE
CGP
% Viability
100
50
0
1 1.3
17-AAG (nM)
1.9 1.9
AZD6244 (nM)
1.9 2
Nutlin-3 (nM)
1.6 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)


CCLE
CGP
% Viability
100
50
0
1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
1.3 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
1.5 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
150
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.1 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

CAL-12T


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.6 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.8 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

CAL-27


CCLE
CGP
% Viability
100
50
0
1.4 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.3 2
AZD6244 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.4 1.6
PD-0325901 (nM)

CAL-85-1


CCLE
CGP
% Viability
17-AAG (nM)
1.1 2
AZD6244 (nM)
2 1.8
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.6 1.9
PD-0332991 (nM)
2 1.6
PLX4720 (nM)
2 2

Calu-3


CCLE
CGP
% Viability
17-AAG (nM)
1.8 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2


Calu-6
CCLE
CGP
% Viability
17-AAG (nM)
1.4 2
AZD0530 (nM)
1.8 2
AZD6244 (nM)
2 1.9
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.3 1
PD-0325901 (nM)
1.3 2
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
1.4 2
Sorafenib (nM)
2 1.8
TAE684 (nM)
1.1 2

CAMA-1


CCLE
CGP
% Viability
100
50
0
1.6 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.5
PD-0332991 (nM)
2 2
PLX4720 (nM)

Capan-2


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
1.5 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.4 1.8
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2


CAS-1
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

CHL-1


CCLE
CGP
% Viability
100
50
0
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.5 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 1.5
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.6
PLX4720 (nM)
2 1.4

CHP-212


CCLE
CGP
% Viability
100
50
0
1.1
1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.1
1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

COLO-205


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1
AZD6244 (nM)
1 1.3
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.1 1.1
PD-0332991 (nM)
2 2
PLX4720 (nM)
1 1.8


COLO-320-HSR
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

COLO-678


CCLE
CGP
% Viability
17-AAG (nM)
1 1.8
AZD6244 (nM)
1.9 1.8
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.8
PD-0325901 (nM)
1.6 1.5
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

COLO-679


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1
AZD6244 (nM)
1 1.1
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.9 2
PD-0325901 (nM)
1 1.5
PD-0332991 (nM)
2 2
PLX4720 (nM)
1 1.3

COLO-741


CCLE
CGP
% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.6 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.3 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.3 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

COR-L23


CCLE
CGP
% Viability
100
50
0
1.6 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 1.9
Nutlin-3 (nM)
2 1.5
PD-0332991 (nM)
2 2
PLX4720 (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)

COR-L105


CCLE
CGP
% Viability
200
100
0
1.9
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
150
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

Daoy


CCLE
CGP
% Viability
17-AAG (nM)
1.9 1.4
AZD6244 (nM)
1.9 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
1.9 1.6

DBTRG-05MG


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.3
AZD6244 (nM)
1.3 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.8 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.3 1.9


CCLE
CGP
% Viability
17-AAG (nM)
1 1.4
AZD0530 (nM)
1.9 2
AZD6244 (nM)
2 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.4 1
PD-0325901 (nM)
2 2
PD-0332991 (nM)
1.5 2
PF2341066 (nM)
1.1 1.3
PHA-665752 (nM)
1.6 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.6
TAE684 (nM)
1.3 1.1

Detroit562


CCLE
CGP
% Viability
17-AAG (nM)
1.8 1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.9 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

DK-MG


CCLE
CGP
% Viability
100
50
0
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.4 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.3
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2

DMS-114


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

DOHH-2


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

DU-145


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

EFE-184


CCLE
CGP
% Viability
100
50
0
1.5 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

EFM-19


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.6
AZD6244 (nM)
2 1.9
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

EFO-21


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

EFO-27


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
2 1.6
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.3
PD-0332991 (nM)
2 1.8


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.8
AZD0530 (nM)
1.1 1.1
AZD6244 (nM)
1.5 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
1 1.6
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.6 1.9
PD-0325901 (nM)
1 1.3
PD-0332991 (nM)
1.4 1.9
PF2341066 (nM)
1.3 1.4
PHA-665752 (nM)
1.9 1.9
PLX4720 (nM)
2 1.9
Sorafenib (nM)
2 1.4
TAE684 (nM)
1.8 1.8

ESS-1


CCLE
CGP
% Viability
100
50
0
1
1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

FADU


CCLE
CGP
% Viability
17-AAG (nM)
1 1.1
AZD6244 (nM)
1.5 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.9 1
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2

G-361


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.6
AZD6244 (nM)
1.3 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.1 1.3
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.3 1.1


CCLE
CGP
% Viability
100
50
0
1.4 1.1
17-AAG (nM)
1.4 1.5
Nutlin-3 (nM)
1.8 1.6
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 1.9
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)

G-402


CCLE
CGP
% Viability
100
50
0
1
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
1.8
1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

GAMG


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
150
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


GB-1
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


GCIY
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

GCT


CCLE
CGP
% Viability
150
100
50
0
1.4 2
17-AAG (nM)
2 1.5
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.8
PD-0332991 (nM)
1.3 2
PLX4720 (nM)
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
1.5 1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
1.9 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

HCC70


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)


HCC1187
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

HCC1395


CCLE
CGP
% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

HCC1569


CCLE
CGP
% Viability
17-AAG (nM)
1.1 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

HCC1806


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.8 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)

HCC1954


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.9
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.8 2
PLX4720 (nM)
2 2

HCT-15


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

HCT-116


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.4
AZD6244 (nM)
1.8 1.3
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.3
PD-0325901 (nM)
1.3 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2


HD-MY-Z
CCLE
CGP
% Viability
17-AAG (nM)
1.4 1
AZD0530 (nM)
2 2
AZD6244 (nM)
1.1 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1 1.4
PD-0325901 (nM)
1 1.4
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
1.8 2
Sorafenib (nM)
2 2
TAE684 (nM)
2 2

HEC-1


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.4
AZD6244 (nM)
1.8 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

HGC-27


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.4 1.3
PLX4720 (nM)
2 2


HH
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

HLE


CCLE
CGP
% Viability
100
50
0
1.6 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

HOS


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

HPAF-II


CCLE
CGP
% Viability
100
50
0
1.8 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.9 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
200
150
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

Hs-578-T


CCLE
CGP
% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

HSC-2


CCLE
CGP
% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

HT-29


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

HT-144


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

HT-1080


CCLE
CGP
% Viability
100
50
0
1.4 1
17-AAG (nM)
1.6 1.1
AZD6244 (nM)
1.8 1.4
Nutlin-3 (nM)
1.6 1.4
PD-0325901 (nM)
1.9 1.4
PD-0332991 (nM)
2 1.4
PLX4720 (nM)

HT-1197


CCLE
CGP
% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

HT-1376


CCLE
CGP
% Viability
17-AAG (nM)
1.6 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

HuCCT1


CCLE
CGP
% Viability
100
50
0
1.1 1.3
17-AAG (nM)
2 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.9 1.9
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

HuP-T3


CCLE
CGP
% Viability
100
50
0
1.4 1.3
17-AAG (nM)
1.5 2
AZD6244 (nM)
2 2
Nilotinib (nM)
1.8 1.6
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

HuP-T4


CCLE
CGP
% Viability
100
50
0
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.1 1
AZD6244 (nM)
1 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.1 1.8
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.8 1.9
PLX4720 (nM)
2 2

IA-LM


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
TAE684 (nM)

IGROV-1


CCLE
CGP
% Viability
100
50
0
1.5 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 1.9
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)

IPC-298


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.3
AZD6244 (nM)
1.1 1.1
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.1 1.1
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
1.9 1.6


IST-MES1
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


CCLE
CGP
% Viability
100
50
0
1.5 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

JVM-3


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.3
AZD0530 (nM)
2 2
AZD6244 (nM)
1.9 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
1.5 2
Nutlin-3 (nM)
1.3 1.1
Paclitaxel (nM)
1.1 2
PD-0325901 (nM)
1.9 2
PD-0332991 (nM)
1.3 1.6
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
1.3 1.5
Sorafenib (nM)
2 2
TAE684 (nM)
1.8 2

K052

CCLE
CGP













KALS-1


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

KARPAS-299


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


KARPAS-422
CCLE
CGP
% Viability
17-AAG (nM)
1 1.9
AZD0530 (nM)
2 2
AZD6244 (nM)
2 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.8 1.4
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
1.9 2
Sorafenib (nM)
2 2
TAE684 (nM)
1.3 1.4


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

KLE


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
TAE684 (nM)

KNS-42


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

KNS-62


CCLE
CGP
% Viability
100
50
0
2
1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.8
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


KNS-81-FD
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

KP-4


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
150
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

KU812


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.8
AZD0530 (nM)
1.5 2
AZD6244 (nM)
1.1 1.1
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
1.4 1.5
Nutlin-3 (nM)
2 1.9
Paclitaxel (nM)
1.3 1
PD-0325901 (nM)
1.3 1.1
PD-0332991 (nM)
2 2
PF2341066 (nM)
1.6 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.9
TAE684 (nM)
2 1.8

KURAMOCHI


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

KYSE-70


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

KYSE-140


CCLE
CGP
% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.5 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

KYSE-150


CCLE
CGP
% Viability
100
50
0
1.3
1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

KYSE-180


CCLE
CGP
% Viability
100
50
0
1.1 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PLX4720 (nM)

KYSE-410


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 1.4
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.1
PLX4720 (nM)
2 2

KYSE-450


CCLE
CGP
% Viability
100
50
0
1.5 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

KYSE-510


CCLE
CGP
% Viability
100
50
0
1.4 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

KYSE-520


CCLE
CGP
% Viability
100
50
0
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 1.9
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

L-363


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

LCLC-103H


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)
2 2
2 1.9

LOXIMVI


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.1
AZD0530 (nM)
1.9 2
AZD6244 (nM)
1.5 1.3
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
2 1.3
Paclitaxel (nM)
1 1.8
PD-0325901 (nM)
1.9 1.4
PD-0332991 (nM)
2 1.5
PF2341066 (nM)
2 1.9
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 1.1
Sorafenib (nM)
2 2
TAE684 (nM)
2 1.6

LP-1


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

LS-123


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


LS-411N
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


LS-513
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

LU-99A


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.3
AZD6244 (nM)
1.5 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.4 2
PD-0332991 (nM)
1.5 2
PLX4720 (nM)
1.8 2

M059J


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

MC116


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

MCF7


CCLE
CGP
% Viability
100
50
0
1.5 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 1.6
Nutlin-3 (nM)
2 1.6
PD-0332991 (nM)
2 2
PLX4720 (nM)

MDA-MB-157


CCLE
CGP
% Viability
100
50
0
2
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2
2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

MDA-MB-175-VII













MDA-MB-415


CCLE
CGP
% Viability
100
50
0
1.1 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PD-0325901 (nM)
PLX4720 (nM)

MDA-MB-453


CCLE
CGP
% Viability
100
50
0
1.1 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

MDA-MB-468


CCLE
CGP
% Viability
17-AAG (nM)
1.5 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.8
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

MEG-01


CCLE
CGP
% Viability
17-AAG (nM)
2 2
AZD0530 (nM)
1.3 1
AZD6244 (nM)
1.5 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
1 1.3
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.4 1
PD-0325901 (nM)
1.9 1.1
PD-0332991 (nM)
2 2
PF2341066 (nM)
1.6 1.3
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.1
TAE684 (nM)
2 2

MEL-HO


CCLE
CGP
% Viability
17-AAG (nM)
2 1.1
AZD6244 (nM)
1.3 1.3
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.5
PD-0325901 (nM)
1 1
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.1 1

MES-SA


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

Mewo


CCLE
CGP
% Viability
17-AAG (nM)
2 1.1
AZD6244 (nM)
2 1.4
Nilotinib (nM)
1.9 2
PD-0325901 (nM)
1.8 1.8
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.9 1.6
PLX4720 (nM)
2 1.5

MFE-280


CCLE
CGP
% Viability
17-AAG (nM)
1.5 1.8
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 1.9

MFE-296


CCLE
CGP
% Viability
100
50
0
1.5 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

MG-63


CCLE
CGP
% Viability
17-AAG (nM)
1.9 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.4
PLX4720 (nM)
2 2


% Viability
AZD6244 (nM)
2 2
Nilotinib (nM)
1.9 2
PD-0325901 (nM)
2 1.9

MHH-ES-1


CCLE
CGP
% Viability
100
50
0
1.4 1.1
17-AAG (nM)
1.5 2
AZD6244 (nM)
1.5 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.1 1.9
PD-0325901 (nM)
1.1 1.1
PD-0332991 (nM)
2 2
PLX4720 (nM)

MIA-PaCa-2


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
1 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1 1.3
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2

MKN7


CCLE
CGP
% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

MKN45


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)

MOLT-16


CCLE
CGP
% Viability
100
50
0
1.4 2
17-AAG (nM)
2 1.9
AZD6244 (nM)
1.9 2
Nilotinib (nM)
1.6 1.1
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.3 1.3
PD-0332991 (nM)
2 2
PLX4720 (nM)

MPP-89


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

MSTO-211H


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.3
AZD0530 (nM)
2 1.8
AZD6244 (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
1.4 1.4
Paclitaxel (nM)
1.3 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.4
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 2
TAE684 (nM)
1.9 1.6

NCI-H23


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H28


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 1.3
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)

NCI-H226


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H358


CCLE
CGP
% Viability
100
50
0
1.1 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.6 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.8 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

NCI-H441


CCLE
CGP
% Viability
17-AAG (nM)
1.5 1.9
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.5
PLX4720 (nM)
1.9 2


% Viability
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.9 2

NCI-H460


CCLE
CGP
% Viability
100
50
0
1
1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

NCI-H520


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.4
PLX4720 (nM)
2 2

NCI-H522


CCLE
CGP
% Viability
100
50
0
1.5 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

NCI-H650


CCLE
CGP
% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)

NCI-H661


CCLE
CGP
% Viability
100
50
0
2
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2
2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

NCI-H727


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

NCI-H747


CCLE
CGP
% Viability
17-AAG (nM)
1 1.3
AZD0530 (nM)
1.9 1.5
AZD6244 (nM)
1.1 1.1
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
2 1.9
PD-0325901 (nM)
1 1.6
PD-0332991 (nM)
2 1.6
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 2
TAE684 (nM)
2 1.1

NCI-H810


CCLE
CGP
% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

NCI-H1048


CCLE
CGP
% Viability
100
50
0
1.4 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

NCI-H1092


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H1155


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H1299


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.3
AZD0530 (nM)
2 2
AZD6244 (nM)
1.9 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.5 1.9
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 2
TAE684 (nM)
1.9 2

NCI-H1355


CCLE
CGP
% Viability
17-AAG (nM)
1.6 1.6
AZD0530 (nM)
2 2
AZD6244 (nM)
2 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.4 1.3
PD-0325901 (nM)
1.8 1.9
PD-0332991 (nM)
2 2
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.8
TAE684 (nM)
1.1 1.4

NCI-H1563


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.6
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0325901 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

NCI-H1573


CCLE
CGP
% Viability
17-AAG (nM)
1.8 1.1
AZD6244 (nM)
1.9 1.9
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2

NCI-H1581


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H1648


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H1650


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.8
PLX4720 (nM)
2 2

NCI-H1651


CCLE
CGP
% Viability
100
50
0
1.3 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

NCI-H1666


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD0530 (nM)
1.8 2
Lapatinib (nM)
1.1 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.9
Paclitaxel (nM)
1.8 2
PD-0325901 (nM)
1.1 1.8
PF2341066 (nM)
2 2
PHA-665752 (nM)
1.9 2
PLX4720 (nM)
1.9 2
Sorafenib (nM)
2 2
TAE684 (nM)
1.6 2

NCI-H1693


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

NCI-H1694


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H1703


CCLE
CGP
% Viability
100
50
0
1.1 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

NCI-H1792


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.8 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

NCI-H1793


CCLE
CGP
% Viability
17-AAG (nM)
1.5 1.6
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
1.6 2
PLX4720 (nM)
2 2


NCI-H1975
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-H2009


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
1.9 1.5
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

NCI-H2030


CCLE
CGP
% Viability
100
50
0
1.1
1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
150
100
50
0
2
1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

NCI-H2052


CCLE
CGP
% Viability
100
50
0
1.1 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PD-0325901 (nM)
PLX4720 (nM)

NCI-H2087


CCLE
CGP
% Viability
100
50
0
1.9 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1.5 1.6
AZD6244 (nM)
2 2
Nilotinib (nM)
1.9 1.8
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
1.8 2
PLX4720 (nM)

NCI-H2122


CCLE
CGP
% Viability
17-AAG (nM)
1 1
AZD6244 (nM)
1.3 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.5
PD-0325901 (nM)
1 1.3
PD-0332991 (nM)
1.4 1.9
PLX4720 (nM)
1.9 2

NCI-H2170


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.4
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

NCI-H2228


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

NCI-H2452


CCLE
CGP
% Viability
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PD-0325901 (nM)
PLX4720 (nM)

NCI-N87


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

NCI-SNU-1


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NCI-SNU-16


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

NUGC-3


CCLE
CGP
% Viability
100
50
0
1.3 1.4
17-AAG (nM)
2 1.5
AZD6244 (nM)
2 2
Nilotinib (nM)
1.9 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
1.8 2
PLX4720 (nM)

OC-314


CCLE
CGP
% Viability
100
50
0
1.6 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)


OCI-AML2
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

OE33


CCLE
CGP
% Viability
100
50
0
1.1 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
1.9 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

ONS-76


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

OPM-2


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

OVCAR-3


CCLE
CGP
% Viability
17-AAG (nM)
1.8 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

OVCAR-4


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

OVCAR-8


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

P12-ICHIKAWA



P31-FUJ


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

PANC-03-27


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 1.9
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

PANC-10-05


CCLE
CGP
% Viability
17-AAG (nM)
1
1.3
AZD6244 (nM)
1.9
1.9
Nilotinib (nM)
2
2
Nutlin-3 (nM)
2
2
PD-0325901 (nM)
2
2
PD-0332991 (nM)
2
2
PLX4720 (nM)
2
2

PC-3


CCLE
CGP
% Viability
17-AAG (nM)
1.8 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.9
PLX4720 (nM)
2 2

PC-14


CCLE
CGP
% Viability
100
50
0
1.1 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


PSN1
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)


Raji
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

RD


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.5 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.4 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

RERF-LC-MS


CCLE
CGP
% Viability
100
50
0
1.4 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2
Nilotinib (nM)
2 1.9
PD-0325901 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD0530 (nM)
2 2
AZD6244 (nM)
1.6 1.1
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nilotinib (nM)
2 1.8
Nutlin-3 (nM)
2 1.3
Paclitaxel (nM)
1 1
PD-0325901 (nM)
1.4 1.4
PD-0332991 (nM)
2 1.9
PF2341066 (nM)
2 1.9
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.6
TAE684 (nM)
2 1.4

RL95-2


CCLE
CGP
% Viability
17-AAG (nM)
1.5 1
AZD0530 (nM)
2 1.3
AZD6244 (nM)
1.6 1.3
Erlotinib (nM)
1.8 2
Lapatinib (nM)
2 1.9
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.3 1.5
PD-0325901 (nM)
1.4 1.4
PD-0332991 (nM)
2 1.6
PF2341066 (nM)
1.9 1.6
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 2
TAE684 (nM)
2 1.3

RPMI-7951


CCLE
CGP
% Viability
100
50
0
1 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.9 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

RPMI-8402


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

RT-112


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.3
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.9 1.9
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 1.8
PLX4720 (nM)
2 2

RT4


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

RVH-421


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.1
AZD6244 (nM)
1 1.3
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.4
PD-0325901 (nM)
1.1 1.5
PD-0332991 (nM)
2 1.8
PLX4720 (nM)
1.1 1.1

Saos-2


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.5
AZD6244 (nM)
2 2
Nilotinib (nM)
1.9 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

SBC-5


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.1
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

SCC-9


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.4 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.8 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

SCC-25


CCLE
CGP
% Viability
100
50
0
1.3 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 1.9
AZD6244 (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)

SF126


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SF295


CCLE
CGP
% Viability
100
50
0
1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)


CCLE
CGP
% Viability
AZD0530 (nM)
Erlotinib (nM)
Lapatinib (nM)
Paclitaxel (nM)
PF2341066 (nM)
PHA-665752 (nM)
Sorafenib (nM)
TAE684 (nM)

SIMA


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SJRH30


CCLE
CGP
% Viability
17-AAG (nM)
1.8 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 2

SJSA-1


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.3
AZD0530 (nM)
2 2
AZD6244 (nM)
2 1.8
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
1.9 1.3
Paclitaxel (nM)
1 1
PD-0325901 (nM)
2 1.3
PD-0332991 (nM)
2 1.8
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 2
Sorafenib (nM)
2 1.9
TAE684 (nM)
2 1.1

SK-CO-1


CCLE
CGP
% Viability
100
50
0
1.1 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.3 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
150
100
50
0
2 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.6 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

SK-HEP-1


CCLE
CGP
% Viability
100
50
0
1.5 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 1.6
PD-0325901 (nM)
2 1.6
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
1.9 1.4
PLX4720 (nM)


SK-LMS-1
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SK-LU-1


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.6
AZD6244 (nM)
2 1.9
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.8
PLX4720 (nM)
2 1.6

SK-MEL-2


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SK-MEL-5


CCLE
CGP
% Viability
17-AAG (nM)
1.5 2
AZD6244 (nM)
1 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1 1.1
Nutlin-3 (nM)
2 1.4
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.1 1.4

SK-MEL-24


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
150
100
50
0
1.5 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.4 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

SK-MEL-30


CCLE
CGP
% Viability
100
50
0
2 1.9
17-AAG (nM)
2 1.6
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
2 1.6
PLX4720 (nM)
1 1.4
AZD6244 (nM)
2 2
Nilotinib (nM)
1.1 2
PD-0325901 (nM)
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}

SK-MES-1


CCLE
CGP
% Viability
100
50
0
1.6 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.4 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


SK-MM-2
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SK-N-AS


CCLE
CGP
% Viability
100
50
0
1.4 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
1 2
AZD6244 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
2 2
PLX4720 (nM)
1.1 1.5
PD-0325901 (nM)


SK-N-DZ
CCLE
CGP
% Viability
17-AAG (nM)
1.5 2
AZD0530 (nM)
2 1.5
AZD6244 (nM)
2 2
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.6 1.1
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.8
PF2341066 (nM)
1.9 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 1.6
Sorafenib (nM)
2 1.9
TAE684 (nM)
1.6 1.4


SK-N-FI
CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SK-OV-3


CCLE
CGP
% Viability
100
50
0
1.6 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)

SNG-M


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

SNU-387


CCLE
CGP
% Viability
100
50
0
1.4 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

SNU-423


CCLE
CGP
% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
AZD6244 (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

SNU-449


CCLE
CGP
% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)
Nutlin-3 (nM)
PD-0332991 (nM)
PLX4720 (nM)


SNU-C2B
CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.9
AZD0530 (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
Paclitaxel (nM)
1.3 1.1
PD-0325901 (nM)
1.9 2
PD-0332991 (nM)
2 2
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
2 1.9
TAE684 (nM)
2 1.9

SUP-T1


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

SW48


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1
Nutlin-3 (nM)
2 1.8
PD-0332991 (nM)
1.6 2
PLX4720 (nM)
2 2


% Viability
AZD6244 (nM)
1.6 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
1.3 2

SW620


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD6244 (nM)
1.4 2
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.5 1.8
PD-0332991 (nM)
2 1.1
PLX4720 (nM)
2 2

SW780


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.1
AZD6244 (nM)
2 1.4
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 1.3
PD-0325901 (nM)
1.6 1.3
PD-0332991 (nM)
1.5 1.9
PLX4720 (nM)
2 2

SW900


CCLE
CGP
% Viability
100
50
0
1.3 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

SW1088


CCLE
CGP
% Viability
100
50
0
1.1 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0332991 (nM)
1.6 2
PLX4720 (nM)

SW1417


CCLE
CGP
% Viability
100
50
0
1.5 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.1 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.5 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
1.3 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

SW1573


CCLE
CGP
% Viability
100
50
0
2
1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2
1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2
2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

SW1990


CCLE
CGP
% Viability
17-AAG (nM)
1 1.1
AZD6244 (nM)
2 1.8
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
1.8 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)
2 1.9


CCLE
CGP
% Viability
150
100
50
0
1.3 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
1.6 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
1.9 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
1.8 1.8
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

T47D


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)

T98G


CCLE
CGP
% Viability
17-AAG (nM)
AZD6244 (nM)
Nilotinib (nM)
Nutlin-3 (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PLX4720 (nM)


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 1.9
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

TE-1


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

TE-5


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

TE-9


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

TE-11


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PF2341066 (nM)
PHA-665752 (nM)
TAE684 (nM)

TE-15


CCLE
CGP
% Viability
17-AAG (nM)
1.1 1.1
AZD0530 (nM)
1.8 1.3
AZD6244 (nM)
1.9 2
Erlotinib (nM)
1.1 2
Lapatinib (nM)
1.4 2
Nutlin-3 (nM)
2 1.9
Paclitaxel (nM)
1.3 1.1
PD-0325901 (nM)
1.3 1.1
PF2341066 (nM)
2 2
PHA-665752 (nM)
1.9 2
PLX4720 (nM)
1.6 2
Sorafenib (nM)
2 2
TAE684 (nM)
2 1.3

TYK-nu


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 1.6
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

U-2-OS


CCLE
CGP
% Viability
17-AAG (nM)
1
1.3
AZD6244 (nM)
2
2
Nilotinib (nM)
2
2
Nutlin-3 (nM)
2
1.6
PD-0325901 (nM)
2
1.8
PD-0332991 (nM)
2
1.8
PLX4720 (nM)
2
2

U-87-MG


CCLE
CGP
% Viability
17-AAG (nM)
AZD0530 (nM)
AZD6244 (nM)
Erlotinib (nM)
Lapatinib (nM)
Nilotinib (nM)
Nutlin-3 (nM)
Paclitaxel (nM)
PD-0325901 (nM)
PD-0332991 (nM)
PF2341066 (nM)
PHA-665752 (nM)
PLX4720 (nM)
Sorafenib (nM)
TAE684 (nM)

U-118-MG


CCLE
CGP
% Viability
100
50
0
1.1 1.4
17-AAG (nM)
2 2
AZD6244 (nM)
2 2
Nilotinib (nM)
2 2
PD-0325901 (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)

UACC-62


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.1 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
1.1 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

UACC-257


CCLE
CGP
% Viability
17-AAG (nM)
1.3 1.5
AZD0530 (nM)
2 2
AZD6244 (nM)
1 1.3
Erlotinib (nM)
2 2
Lapatinib (nM)
2 2
Nutlin-3 (nM)
2 1.9
Paclitaxel (nM)
1.9 1.1
PD-0325901 (nM)
1 1.1
PF2341066 (nM)
2 2
PHA-665752 (nM)
2 2
PLX4720 (nM)
1.1 1.3
Sorafenib (nM)
2 1.8
TAE684 (nM)
2 2

UACC-812


CCLE
CGP
% Viability
AZD0530 (nM)
Erlotinib (nM)
Lapatinib (nM)
PF2341066 (nM)
PHA-665752 (nM)
Sorafenib (nM)
TAE684 (nM)

UM-UC-3


CCLE
CGP
% Viability
100
50
0
1.4 1.3
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)

VMRC-RCZ


CCLE
CGP
% Viability
100
50
0
1.6 1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)
2 2
Nutlin-3 (nM)
2 1.9
PD-0332991 (nM)
2 2
PLX4720 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)
Nilotinib (nM)
PD-0325901 (nM)

WM-115


CCLE
CGP
% Viability
100
50
0
1.1 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
1.9 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 1.5
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
1.5 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)


% Viability
100
50
0
2 1.1
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)

YKG-1


CCLE
CGP
% Viability
17-AAG (nM)
1.4 1.1
AZD6244 (nM)
2 1.6
Nilotinib (nM)
2 2
Nutlin-3 (nM)
2 2
PD-0325901 (nM)
2 2
PD-0332991 (nM)
2 1.3
PLX4720 (nM)
2 2

ZR-75-30


CCLE
CGP
% Viability
100
50
0
1.1 1.4
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
17-AAG (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nutlin-3 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0332991 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PLX4720 (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
AZD6244 (nM)


% Viability
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
Nilotinib (nM)


% Viability
150
100
50
0
2 2
10^{-1} 10^{0} 10^{1} 10^{2} 10^{3} 10^{4} 10^{5}
PD-0325901 (nM)